Az enalapril helye a magasvérnyomás-betegség kezelésében.

Translated title of the contribution: The place of enalapril in the management of hypertension

I. Barna, A. Váradi, P. Kempler, A. Gara, G. Farkas, F. Olajos, R. de Châtel

Research output: Contribution to journalArticle

Abstract

In Hungary the use of angiotensin converting enzyme inhibitor enalapril has emerged as one of the most important drugs in the treatment of hypertension. The aim of our study was to evaluate the antihypertensive effect of enalapril of Hungarian production in combination therapy and alone, according to sexes, to the body mass index, among smokers and non smokers as well as non diabetic and in patients with diabetes (IDDM and NIDDM). The diurnal blood pressure values were registered by a 24 hour ambulatory blood pressure monitor. During the 6 weeks of the enalapril therapy (n = 28) both the daytime (141/84 vs. 135/80 mmHg) and the night-time (130/78 vs. 124/72 mmHg) blood pressure values decreased; the increase of diurnal indices during the therapy (SI/DI 6/8% vs. 8/10) reflect the 24 hour long lasting effect of the drug. The body mass index had no influence on the efficacy of treatment. Our results indicate that enalapril manufactured in Hungary is an effective antihypertensive drug both in monotherapy and in combination, in both sexes (especially in men), irrespective of the body weight, in non-smokers and especially in smokers, in insulin dependent and in non-insulin dependent diabetes mellitus alike.

Original languageHungarian
Pages (from-to)421-424
Number of pages4
JournalOrvosi Hetilap
Volume139
Issue number8
Publication statusPublished - Feb 22 1998

Fingerprint

Enalapril
Hypertension
Hungary
Type 2 Diabetes Mellitus
Antihypertensive Agents
Body Mass Index
Blood Pressure Monitors
Blood Pressure
Therapeutics
Type 1 Diabetes Mellitus
Angiotensin-Converting Enzyme Inhibitors
Pharmaceutical Preparations
Body Weight
Insulin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Barna, I., Váradi, A., Kempler, P., Gara, A., Farkas, G., Olajos, F., & de Châtel, R. (1998). Az enalapril helye a magasvérnyomás-betegség kezelésében. Orvosi Hetilap, 139(8), 421-424.

Az enalapril helye a magasvérnyomás-betegség kezelésében. / Barna, I.; Váradi, A.; Kempler, P.; Gara, A.; Farkas, G.; Olajos, F.; de Châtel, R.

In: Orvosi Hetilap, Vol. 139, No. 8, 22.02.1998, p. 421-424.

Research output: Contribution to journalArticle

Barna, I, Váradi, A, Kempler, P, Gara, A, Farkas, G, Olajos, F & de Châtel, R 1998, 'Az enalapril helye a magasvérnyomás-betegség kezelésében.', Orvosi Hetilap, vol. 139, no. 8, pp. 421-424.
Barna I, Váradi A, Kempler P, Gara A, Farkas G, Olajos F et al. Az enalapril helye a magasvérnyomás-betegség kezelésében. Orvosi Hetilap. 1998 Feb 22;139(8):421-424.
Barna, I. ; Váradi, A. ; Kempler, P. ; Gara, A. ; Farkas, G. ; Olajos, F. ; de Châtel, R. / Az enalapril helye a magasvérnyomás-betegség kezelésében. In: Orvosi Hetilap. 1998 ; Vol. 139, No. 8. pp. 421-424.
@article{4374de9b24b14ce79f5bc406a789a6e8,
title = "Az enalapril helye a magasv{\'e}rnyom{\'a}s-betegs{\'e}g kezel{\'e}s{\'e}ben.",
abstract = "In Hungary the use of angiotensin converting enzyme inhibitor enalapril has emerged as one of the most important drugs in the treatment of hypertension. The aim of our study was to evaluate the antihypertensive effect of enalapril of Hungarian production in combination therapy and alone, according to sexes, to the body mass index, among smokers and non smokers as well as non diabetic and in patients with diabetes (IDDM and NIDDM). The diurnal blood pressure values were registered by a 24 hour ambulatory blood pressure monitor. During the 6 weeks of the enalapril therapy (n = 28) both the daytime (141/84 vs. 135/80 mmHg) and the night-time (130/78 vs. 124/72 mmHg) blood pressure values decreased; the increase of diurnal indices during the therapy (SI/DI 6/8{\%} vs. 8/10) reflect the 24 hour long lasting effect of the drug. The body mass index had no influence on the efficacy of treatment. Our results indicate that enalapril manufactured in Hungary is an effective antihypertensive drug both in monotherapy and in combination, in both sexes (especially in men), irrespective of the body weight, in non-smokers and especially in smokers, in insulin dependent and in non-insulin dependent diabetes mellitus alike.",
author = "I. Barna and A. V{\'a}radi and P. Kempler and A. Gara and G. Farkas and F. Olajos and {de Ch{\^a}tel}, R.",
year = "1998",
month = "2",
day = "22",
language = "Hungarian",
volume = "139",
pages = "421--424",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "8",

}

TY - JOUR

T1 - Az enalapril helye a magasvérnyomás-betegség kezelésében.

AU - Barna, I.

AU - Váradi, A.

AU - Kempler, P.

AU - Gara, A.

AU - Farkas, G.

AU - Olajos, F.

AU - de Châtel, R.

PY - 1998/2/22

Y1 - 1998/2/22

N2 - In Hungary the use of angiotensin converting enzyme inhibitor enalapril has emerged as one of the most important drugs in the treatment of hypertension. The aim of our study was to evaluate the antihypertensive effect of enalapril of Hungarian production in combination therapy and alone, according to sexes, to the body mass index, among smokers and non smokers as well as non diabetic and in patients with diabetes (IDDM and NIDDM). The diurnal blood pressure values were registered by a 24 hour ambulatory blood pressure monitor. During the 6 weeks of the enalapril therapy (n = 28) both the daytime (141/84 vs. 135/80 mmHg) and the night-time (130/78 vs. 124/72 mmHg) blood pressure values decreased; the increase of diurnal indices during the therapy (SI/DI 6/8% vs. 8/10) reflect the 24 hour long lasting effect of the drug. The body mass index had no influence on the efficacy of treatment. Our results indicate that enalapril manufactured in Hungary is an effective antihypertensive drug both in monotherapy and in combination, in both sexes (especially in men), irrespective of the body weight, in non-smokers and especially in smokers, in insulin dependent and in non-insulin dependent diabetes mellitus alike.

AB - In Hungary the use of angiotensin converting enzyme inhibitor enalapril has emerged as one of the most important drugs in the treatment of hypertension. The aim of our study was to evaluate the antihypertensive effect of enalapril of Hungarian production in combination therapy and alone, according to sexes, to the body mass index, among smokers and non smokers as well as non diabetic and in patients with diabetes (IDDM and NIDDM). The diurnal blood pressure values were registered by a 24 hour ambulatory blood pressure monitor. During the 6 weeks of the enalapril therapy (n = 28) both the daytime (141/84 vs. 135/80 mmHg) and the night-time (130/78 vs. 124/72 mmHg) blood pressure values decreased; the increase of diurnal indices during the therapy (SI/DI 6/8% vs. 8/10) reflect the 24 hour long lasting effect of the drug. The body mass index had no influence on the efficacy of treatment. Our results indicate that enalapril manufactured in Hungary is an effective antihypertensive drug both in monotherapy and in combination, in both sexes (especially in men), irrespective of the body weight, in non-smokers and especially in smokers, in insulin dependent and in non-insulin dependent diabetes mellitus alike.

UR - http://www.scopus.com/inward/record.url?scp=0032557002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032557002&partnerID=8YFLogxK

M3 - Article

C2 - 9524425

AN - SCOPUS:0032557002

VL - 139

SP - 421

EP - 424

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 8

ER -